Get the Stockscreener App
1.26
0.80%
0.01
After Hours:
1.28
0.02
+1.59%
Ovid Therapeutics Inc stock is traded at $1.26, with a volume of 613.07K.
It is up +0.80% in the last 24 hours and up +130.35% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$1.25
Open:
$1.26
24h Volume:
613.07K
Relative Volume:
0.32
Market Cap:
$89.60M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-1.68
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+2.44%
1M Performance:
+130.35%
6M Performance:
+152.00%
1Y Performance:
+13.51%
1-Day Range:
$1.22
$1.30
1-Week Range:
$1.15
$1.35
52-Week Range:
$0.2425
$1.47
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.26 | 88.89M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Using RSI to spot recovery in Ovid Therapeutics Inc.Dividend Hike & Intraday High Probability Alerts - Newser
Strategies to average down on Ovid Therapeutics Inc.Layoff News & Real-Time Volume Analysis Alerts - Newser
Evaluating Ovid Therapeutics Inc. with trendline analysisJuly 2025 Snapshot & High Accuracy Trade Alerts - Newser
Will Ovid Therapeutics Inc. continue its uptrendJuly 2025 Final Week & Verified Momentum Stock Watchlist - Newser
Using Bollinger Bands to evaluate Ovid Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Smart tools for monitoring Ovid Therapeutics Inc.’s price actionIndex Update & Weekly Top Stock Performers List - Newser
Using Ichimoku Cloud for Ovid Therapeutics Inc. technicalsWeekly Profit Report & Long-Term Capital Growth Ideas - Newser
Ovid Therapeutics (NASDAQ:OVID) Receives $3.10 Average PT from Brokerages - MarketBeat
Earnings visualization tools for Ovid Therapeutics Inc.2025 Top Decliners & Weekly Return Optimization Plans - Newser
Ovid Therapeutics Inc. stock prediction for this weekEarnings Miss & Daily Technical Stock Forecast Reports - Newser
Analyzing Fate Therapeutics (NASDAQ:FATE) and Ovid Therapeutics (NASDAQ:OVID) - Defense World
Applying big data sentiment scoring on Ovid Therapeutics Inc.Price Action & Precise Trade Entry Recommendations - Newser
Will Ovid Therapeutics Inc. price bounce be sustainableJuly 2025 Macro Moves & Low Risk Entry Point Guides - Newser
Building trade automation scripts for Ovid Therapeutics Inc.Gold Moves & Fast Entry Momentum Trade Alerts - Newser
Will Ovid Therapeutics Inc. stock go up soonStock Surge & AI Based Buy and Sell Signals - Newser
Visualizing Ovid Therapeutics Inc. stock with heatmaps2025 Breakouts & Breakdowns & High Accuracy Swing Trade Signals - Newser
What hedge funds are buying Ovid Therapeutics Inc.Market Trend Summary & Safe Capital Growth Trade Ideas - Lancaster City Council
Aug Highlights: Why is Ovid Therapeutics Inc. stock going upBuy Signal & Comprehensive Market Scan Reports - Lancaster City Council
Why is Ovid Therapeutics Inc. stock going upJuly 2025 Summary & Safe Entry Momentum Stock Tips - beatles.ru
How volatile is Ovid Therapeutics Inc. stockMarket Rally & Smart Allocation Stock Tips - beatles.ru
Is Ovid Therapeutics Inc. subject to activist investor interestJuly 2025 Action & Weekly Setup with ROI Potential - خودرو بانک
Can swing trading help recover from Ovid Therapeutics Inc. lossesPortfolio Gains Report & Safe Entry Zone Identification - Newser
Real time social sentiment graph for Ovid Therapeutics Inc.July 2025 Macro Moves & Daily Growth Stock Tips - Newser
Neurology biopharmas rebound on trial catalysts and Q2 gains - BioWorld MedTech
Is Ovid Therapeutics Inc. forming a bottoming basePortfolio Risk Report & Comprehensive Market Scan Insights - Newser
What indicators show strength in Ovid Therapeutics Inc.Weekly Investment Recap & Free Growth Oriented Trading Recommendations - Newser
Will a bounce in Ovid Therapeutics Inc. offer an exitOptions Play & Step-by-Step Trade Execution Guides - Newser
Can machine learning forecast Ovid Therapeutics Inc. recovery2025 Price Momentum & Reliable Volume Spike Trade Alerts - Newser
What MACD signals say about Ovid Therapeutics Inc.Market Activity Summary & Low Risk High Win Rate Stock Picks - Newser
How to track smart money flows in Ovid Therapeutics Inc.Quarterly Market Review & Smart Allocation Stock Tips - Newser
Custom watchlist performance reports with Ovid Therapeutics Inc.Stock Surge & AI Driven Price Predictions - Newser
How hedge fund analytics apply to Ovid Therapeutics Inc. stockBuy Signal & Breakout Confirmation Trade Signals - Newser
Multi asset correlation models including Ovid Therapeutics Inc.Profit Target & AI Based Trade Execution Alerts - Newser
Full technical analysis of Ovid Therapeutics Inc. stockJuly 2025 Patterns & Precise Swing Trade Entry Alerts - Newser
What recovery options are there for Ovid Therapeutics Inc.Sell Signal & Weekly Return Optimization Plans - Newser
Multi factor analysis applied to Ovid Therapeutics Inc.Market Risk Analysis & Stock Portfolio Risk Management - Newser
Key resistance and support levels for Ovid Therapeutics Inc.2025 Trading Recap & Low Risk High Reward Ideas - Newser
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):